Terms: = Lung cancer AND CUX1, ENSG00000160967, P39880, p75, p200, p110, p100, Nbla10317, CUX, COY1, CDP, CASP, 1523 AND Prognosis
13 results:
1. Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs.
Matsuda Y; Yamashita T; Ye J; Yasukawa M; Yamakawa K; Mukai Y; Machitani M; Daigo Y; Miyagi Y; Yokose T; Oshima T; Ito H; Morinaga S; Kishida T; Minamoto T; Yamada S; Takei J; Kaneko MK; Kojima M; Kaneko S; Masaki T; Hirata M; Haba R; Kontani K; Kanaji N; Miyatake N; Okano K; Kato Y; Masutomi K
J Pathol; 2022 Jun; 257(2):172-185. PubMed ID: 35094384
[TBL] [Abstract] [Full Text] [Related]
2. LEDGF/p75-mediated chemoresistance of mixed-lineage leukemia involves cell survival pathways and super enhancer activators.
Canella A; Van Belle S; Brouns T; Nigita G; Carlon MS; Christ F; Debyser Z
Cancer Gene Ther; 2022 Feb; 29(2):133-140. PubMed ID: 33795806
[TBL] [Abstract] [Full Text] [Related]
3. CD271 is a negative prognostic factor and essential for cell proliferation in lung squamous cell carcinoma.
Mochizuki M; Nakamura M; Sibuya R; Okazaki T; Abe J; Nakagawa T; Takahashi S; Yamazaki T; Imai T; Takano A; Ito H; Yokose T; Miyagi Y; Daigo Y; Sato I; Satoh K; Sugamura K; Yamaguchi K; Tamai K
Lab Invest; 2019 Sep; 99(9):1349-1362. PubMed ID: 31019292
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of the HOXA11 level in patients with lung squamous cancer and insights into potential molecular pathways via bioinformatics analysis.
Zhang R; Zhang TT; Zhai GQ; Guo XY; Qin Y; Gan TQ; Zhang Y; Chen G; Mo WJ; Feng ZB
World J Surg Oncol; 2018 Jun; 16(1):109. PubMed ID: 29914539
[TBL] [Abstract] [Full Text] [Related]
5. p100 functions as a metastasis activator and is targeted by tumor suppressing microRNA-320a in lung cancer.
Xing A; Pan L; Gao J
Thorac Cancer; 2018 Jan; 9(1):152-158. PubMed ID: 29159900
[TBL] [Abstract] [Full Text] [Related]
6. Clinical significance of nucleostemin and proliferating cell nuclear antigen protein expression in non-small cell lung cancer.
Li X; Liu X; Cui D; Wu X; Qian R
J BUON; 2015; 20(4):1088-93. PubMed ID: 26416061
[TBL] [Abstract] [Full Text] [Related]
7. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes.
Cui H; Seubert B; Stahl E; Dietz H; Reuning U; Moreno-Leon L; Ilie M; Hofman P; Nagase H; Mari B; Krüger A
Oncogene; 2015 Jul; 34(28):3640-50. PubMed ID: 25263437
[TBL] [Abstract] [Full Text] [Related]
8. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer.
Zhang T; Zhang DM; Zhao D; Hou XM; Yang TN
J BUON; 2014; 19(3):742-8. PubMed ID: 25261661
[TBL] [Abstract] [Full Text] [Related]
9. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
[TBL] [Abstract] [Full Text] [Related]
10. A novel recombinant immunocasp-6 fusion gene specifically and efficiently suppresses HER2-overexpressing osteosarcoma.
Zhou BG; Liu MY; Qiu XC; Xu YM; Fan QY; Yang AG; Zhang Y; Xia H
Oncol Rep; 2013 Jan; 29(1):276-82. PubMed ID: 23135254
[TBL] [Abstract] [Full Text] [Related]
11. VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway.
Chen CH; Lai JM; Chou TY; Chen CY; Su LJ; Lee YC; Cheng TS; Hong YR; Chou CK; Whang-Peng J; Wu YC; Huang CY
PLoS One; 2009; 4(4):e5052. PubMed ID: 19337377
[TBL] [Abstract] [Full Text] [Related]
12. A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients.
Jatoi A; Jett JR; Sloan J; Novotny P; Ford J; Prabhakar U; Loprinzi CL
Support Care Cancer; 2004 Dec; 12(12):859-63. PubMed ID: 15372221
[TBL] [Abstract] [Full Text] [Related]
13. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.
Bacci G; Ferrari S; Delepine N; Bertoni F; Picci P; Mercuri M; Bacchini P; Brach del Prever A; Tienghi A; Comandone A; Campanacci M
J Clin Oncol; 1998 Feb; 16(2):658-63. PubMed ID: 9469355
[TBL] [Abstract] [Full Text] [Related]
